company background image
AGN logo

Argenica Therapeutics ASX:AGN Stock Report

Last Price

AU$0.83

Market Cap

AU$102.2m

7D

17.7%

1Y

118.4%

Updated

23 Jun, 2024

Data

Company Financials

Argenica Therapeutics Limited

ASX:AGN Stock Report

Market Cap: AU$102.2m

AGN Stock Overview

Engages in the research and development of a neuroprotective therapeutic drug in Australia.

AGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Argenica Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Argenica Therapeutics
Historical stock prices
Current Share PriceAU$0.83
52 Week HighAU$0.90
52 Week LowAU$0.29
Beta0.84
11 Month Change17.73%
3 Month Change36.07%
1 Year Change118.42%
33 Year Change315.00%
5 Year Changen/a
Change since IPO219.23%

Recent News & Updates

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Recent updates

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Jul 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Apr 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Nov 30
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Shareholder Returns

AGNAU PharmaceuticalsAU Market
7D17.7%-2.0%0.8%
1Y118.4%64.6%10.3%

Return vs Industry: AGN exceeded the Australian Pharmaceuticals industry which returned 64.6% over the past year.

Return vs Market: AGN exceeded the Australian Market which returned 10.3% over the past year.

Price Volatility

Is AGN's price volatile compared to industry and market?
AGN volatility
AGN Average Weekly Movement11.1%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement8.3%
10% most volatile stocks in AU Market16.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: AGN's share price has been volatile over the past 3 months.

Volatility Over Time: AGN's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2019n/aLiz Dallimoreargenica.com.au

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Argenica Therapeutics Limited Fundamentals Summary

How do Argenica Therapeutics's earnings and revenue compare to its market cap?
AGN fundamental statistics
Market capAU$102.18m
Earnings (TTM)-AU$4.67m
Revenue (TTM)AU$2.72m

37.5x

P/S Ratio

-21.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGN income statement (TTM)
RevenueAU$2.72m
Cost of RevenueAU$0
Gross ProfitAU$2.72m
Other ExpensesAU$7.40m
Earnings-AU$4.67m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.038
Gross Margin100.00%
Net Profit Margin-171.52%
Debt/Equity Ratio0%

How did AGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.